Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | NGS: a valuable tool for elucidating the genetic landscape of AML

Torsten Haferlach • 10 Apr 2019
EBMT 2019
Acute Myeloid Leukemia Leukemia

Torsten Haferlach, MD, of Munich Leukemia Laboratory, Munich, Germany, discusses how next-generation sequencing (NGS) can significantly facilitate the uncovering of genetic mutations associated with acute myeloid leukemia (AML). Speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany, Prof. Haferlach reports that NGS can enable scientists to gain important information for diagnosis, prognostication and measurable residual disease (MRD) in the context of AML.

More from Torsten Haferlach

3:33
The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
Torsten Haferlach • 9 Dec 2023
1:52
Implementing AI in hematology and the challenges this will overcome
Torsten Haferlach • 9 Dec 2023
2:57
Why do we need AI in the hematology clinic?
Torsten Haferlach • 9 Dec 2023
1:53
Role of NGS in acute leukemias
Torsten Haferlach • 17 Sep 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals